<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755244</url>
  </required_header>
  <id_info>
    <org_study_id>AT148005</org_study_id>
    <nct_id>NCT04755244</nct_id>
  </id_info>
  <brief_title>A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)</brief_title>
  <official_title>A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Venetoclax and Azacitidine in Patients With Acute Myeloid Leukemia (AML) (ASPEN-05)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALX Oncology Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALX Oncology Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with&#xD;
      venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1 will consist of a dose escalation of evorpacept (ALX148) in combination with&#xD;
      venetoclax and azacitidine to evaluate safety and tolerability, and to identify the&#xD;
      recommended Phase 2 dose of evorpacept (ALX148) in combination with venetoclax and&#xD;
      azacitidine. The Phase 2 will evaluate the efficacy of evorpacept (ALX148) in combination&#xD;
      with venetoclax and azacitidine for patients with AML.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Composite complete remission rate (CRc)</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Number of participants achieving a complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) per European LeukemiaNet (ELN) 2017 criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>AML, Adult</condition>
  <arm_group>
    <arm_group_label>evorpacept (ALX148) + venetoclax + azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1a: Participants will receive escalating doses of evorpacept (ALX148) in combination with venetoclax and azacitidine&#xD;
Phase 1b/2: Participants will receive evorpacept (ALX148) at the recommended Phase 2 dose in combination with venetoclax and azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>evorpacept</intervention_name>
    <description>Fusion protein that blocks CD47-SIRPalpha pathway</description>
    <arm_group_label>evorpacept (ALX148) + venetoclax + azacitidine</arm_group_label>
    <other_name>ALX148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venetoclax</intervention_name>
    <description>BCL-2 inhibitor</description>
    <arm_group_label>evorpacept (ALX148) + venetoclax + azacitidine</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Hypomethylating agent (HMA)</description>
    <arm_group_label>evorpacept (ALX148) + venetoclax + azacitidine</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologically or histologically confirmed diagnosis of relapsed/refractory or newly&#xD;
             diagnosed AML per WHO 2016 classification.&#xD;
&#xD;
          -  Phase 1a: AML that is relapsed/refractory or that is previously untreated in patients&#xD;
             not considered suitable for intensive induction therapy.&#xD;
&#xD;
          -  Phase 1b: AML that is relapsed/refractory after prior treatment with a HMA-based&#xD;
             regimen.&#xD;
&#xD;
          -  Phase 2: Previously untreated AML in patients who are not considered suitable&#xD;
             candidates for intensive induction therapy.&#xD;
&#xD;
          -  Adequate renal and liver function.&#xD;
&#xD;
          -  Age â‰¥18 years.&#xD;
&#xD;
          -  Adequate performance status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In Phase 1a and 1b, patients that have undergone prior allo-HSCT must be at least 3&#xD;
             months post-HSCT, without uncontrolled graft-versus-host disease (GVHD). For Phase 2,&#xD;
             patients that have undergone prior allo-HSCT are excluded.&#xD;
&#xD;
          -  Patients with newly diagnosed AML with favorable risk cytogenetics such as t(8;21),&#xD;
             inv(16), or t(16;16) as per the NCCN Guidelines Version 3, 2019 for AML.&#xD;
&#xD;
          -  Patients with acute promyelocytic leukemia (APL).&#xD;
&#xD;
          -  Prior treatment with any anti-CD47 or anti-SIRPalpha (signal regulatory protein alpha)&#xD;
             agent.&#xD;
&#xD;
          -  Known active viral infections, including hepatitis B and C, human immunodeficiency&#xD;
             virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2&#xD;
             (severe acute respiratory syndrome coronavirus 2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abraham Fong, MD, PhD</last_name>
    <phone>650-466-7125</phone>
    <email>info@alxoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALX148</keyword>
  <keyword>CD47</keyword>
  <keyword>SIRPalpha</keyword>
  <keyword>azacitidine</keyword>
  <keyword>venetoclax</keyword>
  <keyword>evorpacept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

